An unusual Senate hearing venue highlighted old arguments over FDA’s statutory standard for premarket approval and expanded access in the current political context of accelerating access for pediatric rare diseases and concerns over high drug costs.
The Senate Homeland Security & Governmental Affairs Committee held the Feb. 25 hearing, titled